Literature DB >> 26723243

Organizing Pneumonia Induced by Nivolumab in a Patient with Metastatic Melanoma.

Kazuhisa Nakashima1, Tateaki Naito2, Shota Omori1, Shusuke Yoshikawa3, Masahiro Endo4, Yoshio Kiyohara3, Toshiaki Takahashi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26723243     DOI： 10.1016/j.jtho.2015.10.004

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  12 in total

1.  Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.

Authors:  Myriam Delaunay; Jacques Cadranel; Amélie Lusque; Nicolas Meyer; Valérie Gounant; Denis Moro-Sibilot; Jean-Marie Michot; Judith Raimbourg; Nicolas Girard; Florian Guisier; David Planchard; Anne-Cécile Metivier; Pascale Tomasini; Eric Dansin; Maurice Pérol; Marion Campana; Oliver Gautschi; Martin Früh; Jean-David Fumet; Clarisse Audigier-Valette; Sébastien Couraud; Stéphane Dalle; Marie-Thérèse Leccia; Marion Jaffro; Samia Collot; Grégoire Prévot; Julie Milia; Julien Mazieres
Journal:  Eur Respir J       Date:  2017-08-10       Impact factor: 16.671

2.  Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP).

Authors:  Tsukasa Ishiwata; Takahiro Ebata; Shunichiro Iwasawa; Jun Matsushima; Satoshi Ota; Yukio Nakatani; Kenji Tsushima; Yuji Tada; Koichiro Tatsumi; Yuichi Takiguchi
Journal:  Intern Med       Date:  2017-08-10       Impact factor: 1.271

3.  Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma.

Authors:  Naoya Yamazaki; Yoshio Kiyohara; Hisashi Uhara; Hajime Iizuka; Jiro Uehara; Fujio Otsuka; Yasuhiro Fujisawa; Tatsuya Takenouchi; Taiki Isei; Keiji Iwatsuki; Hiroshi Uchi; Hironobu Ihn; Hironobu Minami; Hideaki Tahara
Journal:  Cancer Sci       Date:  2017-05-11       Impact factor: 6.716

Review 4.  Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials.

Authors:  Ricardo Costa; Benedito A Carneiro; Mark Agulnik; Alfred W Rademaker; Sachin G Pai; Victoria M Villaflor; Massimo Cristofanilli; Jeffrey A Sosman; Francis J Giles
Journal:  Oncotarget       Date:  2017-01-31

5.  Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer.

Authors:  Eun Young Kim; Inkeun Park; Young Saing Kim; Hee Kyung Ahn; Hee Young Lee; Jeong Ho Kim
Journal:  Thorac Cancer       Date:  2019-02-07       Impact factor: 3.500

6.  A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab.

Authors:  Paraskevi Fragkou; Maria Souli; Maria Theochari; Christina Kontopoulou; Stelios Loukides; Anna Koumarianou
Journal:  Drug Target Insights       Date:  2016-05-22

7.  Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?

Authors:  Sameep Sehgal; Vamsidhar Velcheti; Sanjay Mukhopadhyay; James K Stoller
Journal:  Respir Med Case Rep       Date:  2016-09-08

8.  Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab.

Authors:  Ryoji Kato; Hidetoshi Hayashi; Junko Tanizaki; Kaoru Tanaka; Masayuki Takeda; Kazuhiko Nakagawa
Journal:  ESMO Open       Date:  2017-03-28

9.  Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series.

Authors:  Padmastuti Akella; Sundaravadivel Loganathan; Vishal Jindal; Jamal Akhtar; Amos Lal
Journal:  Respir Med Case Rep       Date:  2018-11-12

10.  Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapy.

Authors:  Satoshi Watanabe; Takeshi Ota; Masachika Hayashi; Hiroyuki Ishikawa; Aya Otsubo; Satoshi Shoji; Koichiro Nozaki; Kosuke Ichikawa; Rie Kondo; Takao Miyabayashi; Satoru Miura; Hiroshi Tanaka; Tetsuya Abe; Masaaki Okajima; Masaki Terada; Takashi Ishida; Akira Iwashima; Kazuhiro Sato; Hirohisa Yoshizawa; Toshiaki Kikuchi
Journal:  Cancer Med       Date:  2020-03-09       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.